Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

BACKGROUND: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported ou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Gastroenterol
Hauptverfasser: Panés, Julián, Su, Chinyu, Bushmakin, Andrew G, Cappelleri, Joseph C, Mamolo, Carla, Healey, Paul
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323227/
https://ncbi.nlm.nih.gov/pubmed/25651782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0239-9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge